|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 31/7064 | (2006.01) |
| A61K 31/7076 | (2006.01) |
| (11) | Number of the document | 2203462 |
| (13) | Kind of document | T |
| (96) | European patent application number | 08732818.3 |
| Date of filing the European patent application | 2008-03-26 | |
| (97) | Date of publication of the European application | 2010-07-07 |
| (45) | Date of publication and mention of the grant of the patent | 2014-05-21 |
| (46) | Date of publication of the claims translation | 2014-09-25 |
| (86) | Number | PCT/US2008/058183 |
| Date | 2008-03-26 |
| (87) | Number | WO 2008/121634 |
| Date | 2008-10-09 |
| (30) | Number | Date | Country code |
| 909315 P | 2007-03-30 | US | |
| 982309 P | 2007-10-24 | US | |
| 53015 | 2008-03-21 | US |
| (72) |
SOFIA, Michael, Joseph, US
DU, Jinfa, US
WANG, Peiyuan, US
NAGARATHNAM, Dhanapalan, US
|
| (73) |
Gilead Pharmasset LLC,
Gilead Sciences, Inc. 333 Lakeside Drive, Foster City, CA 94404,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Nukleozidų fosforamidato provaistai |
| NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS |
| Payment date | Validity (years) | Amount | |
| 2026-02-26 | 19 | 347.00 EUR |
| 2027-03-26 |